Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy

HBM7575/SKB575 blocks the interaction between TSLP and its receptor, inhibiting signalling pathways and Th2 immune cell activation. Credit: alicancomertpay / Shutterstock.com.